Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Obenauf, AC; Zou, Y; Ji, AL; Vanharanta, S; Shu, W; Shi, H; Kong, X; Bosenberg, MC; Wiesner, T; Rosen, N; Lo, RS; Massagué, J.
Therapy-induced tumour secretomes promote resistance and tumour progression.
Nature. 2015; 520(7547): 368-372. [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG


Autor/innen der Med Uni Graz:
Obenauf Anna Christina
Wiesner Thomas

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Number of Figures: 13
| | | | | | | | | | | | |
Drug resistance invariably limits the clinical efficacy of targeted therapy with kinase inhibitors against cancer. Here we show that targeted therapy with BRAF, ALK or EGFR kinase inhibitors induces a complex network of secreted signals in drug-stressed human and mouse melanoma and human lung adenocarcinoma cells. This therapy-induced secretome stimulates the outgrowth, dissemination and metastasis of drug-resistant cancer cell clones and supports the survival of drug-sensitive cancer cells, contributing to incomplete tumour regression. The tumour-promoting secretome of melanoma cells treated with the kinase inhibitor vemurafenib is driven by downregulation of the transcription factor FRA1. In situ transcriptome analysis of drug-resistant melanoma cells responding to the regressing tumour microenvironment revealed hyperactivation of several signalling pathways, most prominently the AKT pathway. Dual inhibition of RAF and the PI(3)K/AKT/mTOR intracellular signalling pathways blunted the outgrowth of the drug-resistant cell population in BRAF mutant human melanoma, suggesting this combination therapy as a strategy against tumour relapse. Thus, therapeutic inhibition of oncogenic drivers induces vast secretome changes in drug-sensitive cancer cells, paradoxically establishing a tumour microenvironment that supports the expansion of drug-resistant clones, but is susceptible to combination therapy.
Find related publications in this database (using NLM MeSH Indexing)
Adenocarcinoma - drug therapy Adenocarcinoma - metabolism Adenocarcinoma - pathology Adenocarcinoma - secretion
Animals -
Cell Line, Tumor -
Cell Movement - drug effects
Cell Proliferation - drug effects
Cell Survival - drug effects
Clone Cells - drug effects Clone Cells - pathology
Disease Progression -
Down-Regulation - drug effects
Drug Resistance, Neoplasm - drug effects
Enzyme Activation - drug effects
Female -
Humans -
Lung Neoplasms - drug therapy Lung Neoplasms - metabolism Lung Neoplasms - pathology Lung Neoplasms - secretion
Melanoma - drug therapy Melanoma - metabolism Melanoma - pathology Melanoma - secretion
Metabolome - drug effects
Mice -
Neoplasm Metastasis - drug therapy Neoplasm Metastasis - pathology
Protein Kinase Inhibitors - pharmacology Protein Kinase Inhibitors - therapeutic use
Proto-Oncogene Proteins B-raf - antagonists & inhibitors
Proto-Oncogene Proteins c-akt - metabolism
Proto-Oncogene Proteins c-fos - deficiency
Receptor Protein-Tyrosine Kinases - antagonists & inhibitors
Receptor, Epidermal Growth Factor - antagonists & inhibitors
Signal Transduction - drug effects
Tumor Microenvironment - drug effects

© Med Uni Graz Impressum